Current Cardiology Reports

, 15:420

The Evolving Role of Cardiac Troponin in the Evaluation of Cardiac Disorders

Ischemic Heart Disease (D Mukherjee, Section Editor)

DOI: 10.1007/s11886-013-0420-0

Cite this article as:
Anaya, P. & Moliterno, D.J. Curr Cardiol Rep (2013) 15: 420. doi:10.1007/s11886-013-0420-0
Part of the following topical collections:
  1. Topical Collection on Ischemic Heart Disease

Abstract

Due to their tissue specificity and ease of detection, the cardiac troponins (cTn) have emerged as the most important and most utilized biomarkers for the diagnosis of acute myocardial infarction (AMI). The recent achievement of greater sensitivity by cTn assay systems, however, has resulted in the detection of cTn in a wide array of medical conditions, highlighting myocardial cellular necrosis as a feature in several, seemingly unrelated medical conditions, yet complicating the interpretation of a positive test. Since elevated cTn levels are associated with worse clinical outcomes and, thereby, influence medical decisions, careful consideration should be given to the method by which these biomarkers are measured, the patient population on which the test is being applied, and applicable thresholds based on particular clinical conditions. The objective of this review is to trace the clinical evolution of the cTn biomarker from a test for AMI to a general marker of myocardial cellular necrosis with clinically important prognostic information.

Keywords

BiomarkerCardiac troponinHigh-sensitivity99th percentileMyocardial necrosisAcute coronary syndromeAcute myocardial infarctionCardiotoxicityCardiac disordersEvaluation

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Cardiovascular Medicine, Gill Heart InstituteUniversity of KentuckyLexingtonUSA